Biodistribution of HuCC49ΔCH2-β-galactosidase in colorectal cancer xenograft model

International Journal of Pharmaceutics

Volumn 386, Issue 1-2, 2010, Pages 208-215

  Yu, Yanke ^a   Fang, Lanyan ^a   Sun, Duxin ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

ADEPT; Antibody; Biodistribution; HuCC49 CH2; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; BETA GALACTOSIDASE; TUMOR ASSOCIATED GLYCOPROTEIN 72 ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; B72.3 ANTIBODY; CANCER ANTIBODY; GLYCOPROTEIN; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; TUMOR ASSOCIATED ANTIGEN 72; TUMOR-ASSOCIATED ANTIGEN 72;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; AREA UNDER THE CURVE; ARTICLE; BINDING SITE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TARGETING; DRUG TISSUE LEVEL; HEART; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY PARENCHYMA; LIVER; LUNG PARENCHYMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; STOMACH; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR XENOGRAFT; ANIMAL; ANTIBODY COMBINING SITE; BLOOD; COLORECTAL TUMOR; COLORIMETRY; FEMALE; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METABOLISM; NUDE MOUSE; TISSUE DISTRIBUTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; BETA-GALACTOSIDASE; BINDING SITES, ANTIBODY; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; COLORIMETRY; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOCONJUGATES; INJECTIONS, INTRAVENOUS; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 74149084810     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.11.020     Document Type: Article

References (35)

1. Agnese D.M., Abdessalam S.F., Burak Jr. W.E., Arnold M.W., Soble D., Hinkle G.H., Young D., Khazaeli M.B., and Martin Jr. E.W. Pilot study using a humanized CC49 monoclonal antibody (HuCC49DeltaCH2) to localize recurrent colorectal carcinoma. Ann. Surg. Oncol. 11 (2004) 197-202
2. Ahn J.H., Kim T.W., Lee J.H., Min Y.J., Kim J.G., Kim J.C., Yu C.S., Kim W.K., Kang Y.K., and Lee J.S. Oral doxifluridine plus leucovorin in metastatic colorectal cancer: randomized phase II trial with intravenous 5-fluorouracil plus leucovorin. Am. J. Clin. Oncol. 26 (2003) 98-102
3. Alderson R.F., Toki B.E., Roberge M., Geng W., Basler J., Chin R., Liu A., Ueda R., Hodges D., Escandon E., Chen T., Kanavarioti T., Babe L., Senter P.D., Fox J.A., and Schellenberger V. Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT). Bioconjug. Chem. 17 (2006) 410-418
4. Arnold M.W., Young D.M., Hitchcock C.L., Barbera-Guillem E., Nieroda C., and Martin Jr. E.W. Staging of colorectal cancer: biology vs. morphology. Dis. Colon Rectum 41 (1998) 1482-1487
5. Bagshawe K.D. Antibody directed enzymes revive anti-cancer prodrugs concept. Br. J. Cancer 56 (1987) 531-532
6. Bagshawe K.D., Springer C.J., Searle F., Antoniw P., Sharma S.K., Melton R.G., and Sherwood R.F. A cytotoxic agent can be generated selectively at cancer sites. Br. J. Cancer 58 (1988) 700-703
7. Baranowska-Kortylewicz J., Abe M., Nearman J., and Enke C.A. Emerging role of platelet-derived growth factor receptor-beta inhibition in radioimmunotherapy of experimental pancreatic cancer. Clin. Cancer Res. 13 (2007) 299-306
8. Bertsch D.J., Burak Jr. W.E., Young D.C., Arnold M.W., and Martin Jr. E.W. Radioimmunoguided surgery system improves survival for patients with recurrent colorectal cancer. Surgery 118 (1995) 634-638 (discussion 638-9)
9. Bertsch D.J., Burak Jr. W.E., Young D.C., Arnold M.W., and Martin Jr. E.W. Radioimmunoguided surgery for colorectal cancer. Ann. Surg. Oncol. 3 (1996) 310-316
10. BioTek, 2001. http://www.biotek.com/products/tech_res_detail.php?id=52.
11. Cao X., Fang L., Gibbs S., Huang Y., Dai Z., Wen P., Zheng X., Sadee W., and Sun D. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother. Pharmacol. 59 (2007) 495-505
12. Cheng H., Cao X., Xian M., Fang L., Cai T.B., Ji J.J., Tunac J.B., Sun D., and Wang P.G. Synthesis and enzyme-specific activation of carbohydrate-geldanamycin conjugates with potent anticancer activity. J. Med. Chem. 48 (2005) 645-652
13. Cheng T.L., Wei S.L., Chen B.M., Chern J.W., Wu M.F., Liu P.W., and Roffler S.R. Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug. Br. J. Cancer 79 (1999) 1378-1385
14. Cohen A.M., Martin Jr. E.W., Lavery I., Daly J., Sardi A., Aitken D., Bland K., Mojzisik C., and Hinkle G. Radioimmunoguided surgery using iodine 125 B72.3 in patients with colorectal cancer. Arch. Surg. 126 (1991) 349-352
15. Fang L., Battisti R.F., Cheng H., Reigan P., Xin Y., Shen J., Ross D., Chan K.K., Martin Jr. E.W., Wang P.G., and Sun D. Enzyme specific activation of benzoquinone ansamycin prodrugs using HuCC49DeltaCH2-beta-galactosidase conjugates. J. Med. Chem. 49 (2006) 6290-6297
16. Fang L., Holford N.H., Hinkle G., Cao X., Xiao J.J., Bloomston M., Gibbs S., Saif O.H., Dalton J.T., Chan K.K., Schlom J., Martin Jr. E.W., and Sun D. Population pharmacokinetics of humanized monoclonal antibody HuCC49deltaCH2 and murine antibody CC49 in colorectal cancer patients. J. Clin. Pharmacol. 47 (2007) 227-237
17. Fang L., and Sun D. Predictive physiologically based pharmacokinetic model for antibody-directed enzyme prodrug therapy. Drug Metab. Dispos. 36 (2008) 1153-1165
18. Francis R.J., Mather S.J., Chester K., Sharma S.K., Bhatia J., Pedley R.B., Waibel R., Green A.J., and Begent R.H. Radiolabelling of glycosylated MFE-23::CPG2 fusion protein (MFECP1) with 99mTc for quantitation of tumour antibody-enzyme localisation in antibody-directed enzyme pro-drug therapy (ADEPT). Eur. J. Nucl. Med. Mol. Imaging 31 (2004) 1090-1096
19. Frankel A.E. Antibody-toxin hybrids: a clinical review of their use. J. Biol. Response Mod. 4 (1985) 437-446
20. Fuchs C.S., Moore M.R., Harker G., Villa L., Rinaldi D., and Hecht J.R. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J. Clin. Oncol. 21 (2003) 807-814
21. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., Meropol N.J., Novotny W.F., Lieberman G., Griffing S., and Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21 (2003) 60-65
22. LaValle G.J., Martinez D.A., Sobel D., DeYoung B., and Martin Jr. E.W. Assessment of disseminated pancreatic cancer: a comparison of traditional exploratory laparotomy and radioimmunoguided surgery. Surgery 122 (1997) 867-871 discussion 871-3
23. Mandler R., Wu C., Sausville E.A., Roettinger A.J., Newman D.J., Ho D.K., King C.R., Yang D., Lippman M.E., Landolfi N.F., Dadachova E., Brechbiel M.W., and Waldmann T.A. Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines. J. Natl. Cancer Inst. 92 (2000) 1573-1581
24. Martin Jr. E.W., and Thurston M.O. Intraoperative radioimmunodetection. Semin. Surg. Oncol. 15 (1998) 205-208
25. Meredith R.F., Alvarez R.D., Partridge E.E., Khazaeli M.B., Lin C.Y., Macey D.J., Austin Jr. J.M., Kilgore L.C., Grizzle W.E., Schlom J., and LoBuglio A.F. Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study. Cancer Biother. Radiopharm. 16 (2001) 305-315
26. Milenic D.E., Garmestani K., Chappell L.L., Dadachova E., Yordanov A., Ma D., Schlom J., and Brechbiel M.W. In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. Nucl. Med. Biol. 29 (2002) 431-442
27. Nieroda C.A., Mojzisik C., Sardi A., Ferrara P.J., Hinkle G., Thurston M.O., and Martin Jr. E.W. Radioimmunoguided surgery in primary colon cancer. Cancer Detect Prev. 14 (1990) 651-656
28. Senter P.D., and Springer C.J. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv. Drug Deliv. Rev. 53 (2001) 247-264
29. Sharma S.K., Bagshawe K.D., and Begent R.H. Advances in antibody-directed enzyme prodrug therapy. Curr. Opin. Invest. Drugs 6 (2005) 611-615
30. Sharma S.K., Bagshawe K.D., Melton R.G., and Sherwood R.F. Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial. Cell Biophys. 21 (1992) 109-120
31. Springer C.J., and Niculescu-Duvaz I.I. Antibody-directed enzyme prodrug therapy (ADEPT): a review. Adv. Drug Deliv. Rev. 26 (1997) 151-172
32. Stribbling S.M., Martin J., Pedley R.B., Boden J.A., Sharma S.K., and Springer C.J. Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft. Cancer Chemother. Pharmacol. 40 (1997) 277-284
33. Sun D., Bloomston M., Hinkle G., Al-Saif O.H., Hall N.C., Povoski S.P., Arnold M.W., and Martin Jr. E.W. Radioimmunoguided surgery (RIGS), PET/CT image-guided surgery, and fluorescence image-guided surgery: past, present, and future. J. Surg. Oncol. 96 (2007) 297-308
34. Tietze L.F., and Krewer B. Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies. Chem. Biol. Drug Des. 74 (2009) 205-211
35. Xiao J., Horst S., Hinkle G., Cao X., Kocak E., Fang J., Young D., Khazaeli M., Agnese D., Sun D., and Martin Jr. E. Pharmacokinetics and clinical evaluation of 125I-radiolabeled humanized CC49 monoclonal antibody (HuCC49deltaC(H)2) in recurrent and metastatic colorectal cancer patients. Cancer Biother. Radiopharm. 20 (2005) 16-26